Korro Bio price to sales ratio KRRO

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 74.1×
6-year median: 10.4×
Against its 6-year history: 95th; percentile: 0 is its lowest day, 100 its highest
6-year range: 2.6× to 85.4×
Peer median: 1.4×

Korro Bio's price to sales ratio is 74.1× as of Oct 23, 2026.

That is above its 6-year median of 10.4×, higher than on 95% of days in the last 6 years.

Over that time it ranged from 2.6× in Mar 2022 to 85.4× in Sep 2026.

The median for 10 large drugmakers of a similar size is 1.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	74.1×	10.3×	85.4×
2025	10.4×	7.3×	10.5×
2024	n/m a value too high to mean anything
2023	n/m a value too high to mean anything
2022	8.3×	2.6×	8.3×
2021	7.4×	6.1×	58.5×
2020	37.5×	13.4×	37.5×

Against its peers

Companies in Drug Manufacturers - General nearest Korro Bio's size, closest first, today.

Company	Price to sales ratio
KRROKorro Bio	74.1×
NATRNatures Sunshine Products	0.4×
LFVNLifevantage	0.4×
ARVNArvinas	1.5×
SPROSpero Therapeutics	1.4×
PBYIPuma Biotechnology	2.5×
IRWDIronwood Pharmaceuticals	1.5×
ZVRAZevra Therapeutics	4.3×
CRMDCorMedix	1.3×
ATNMActinium Pharmaceuticals	n/m
COLLCollegium Pharmaceutical	0.9×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Korro Bio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.